Tarsus Pharmaceuticals Inc (TARS)
30.98
-2.16
(-6.52%)
USD |
NASDAQ |
Jun 14, 16:00
31.00
+0.02
(+0.06%)
Pre-Market: 20:00
Tarsus Pharmaceuticals Enterprise Value: 901.89M for June 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 14, 2024 | 901.89M |
| June 13, 2024 | 983.49M |
| June 12, 2024 | 968.38M |
| June 11, 2024 | 963.09M |
| June 10, 2024 | 956.29M |
| June 07, 2024 | 947.98M |
| June 06, 2024 | 951.38M |
| June 05, 2024 | 1.002B |
| June 04, 2024 | 978.58M |
| June 03, 2024 | 964.23M |
| May 31, 2024 | 976.69M |
| May 30, 2024 | 1.044B |
| May 29, 2024 | 1.042B |
| May 28, 2024 | 1.029B |
| May 24, 2024 | 1.054B |
| May 23, 2024 | 1.098B |
| May 22, 2024 | 1.083B |
| May 21, 2024 | 1.161B |
| May 20, 2024 | 1.195B |
| May 17, 2024 | 1.176B |
| May 16, 2024 | 1.189B |
| May 15, 2024 | 1.186B |
| May 14, 2024 | 1.167B |
| May 13, 2024 | 1.181B |
| May 10, 2024 | 1.129B |
| Date | Value |
|---|---|
| May 09, 2024 | 1.017B |
| May 08, 2024 | 1.143B |
| May 07, 2024 | 1.168B |
| May 06, 2024 | 1.130B |
| May 03, 2024 | 1.124B |
| May 02, 2024 | 1.040B |
| May 01, 2024 | 958.77M |
| April 30, 2024 | 918.73M |
| April 29, 2024 | 944.80M |
| April 26, 2024 | 941.77M |
| April 25, 2024 | 948.20M |
| April 24, 2024 | 968.97M |
| April 23, 2024 | 1.005B |
| April 22, 2024 | 951.22M |
| April 19, 2024 | 956.89M |
| April 18, 2024 | 972.37M |
| April 17, 2024 | 1.032B |
| April 16, 2024 | 1.050B |
| April 15, 2024 | 1.051B |
| April 12, 2024 | 1.097B |
| April 11, 2024 | 1.177B |
| April 10, 2024 | 1.086B |
| April 09, 2024 | 1.100B |
| April 08, 2024 | 1.061B |
| April 05, 2024 | 1.043B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
111.68M
Minimum
May 04 2022
1.195B
Maximum
May 20 2024
401.53M
Average
327.33M
Median
Dec 03 2021
Enterprise Value Benchmarks
| Pacira BioSciences Inc | 1.504B |
| CEL-SCI Corp | 65.10M |
| AIM ImmunoTech Inc | 15.35M |
| IGC Pharma Inc | 25.36M |
| NovaBay Pharmaceuticals Inc | 3.382M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -35.73M |
| Revenue (Quarterly) | 27.61M |
| Total Expenses (Quarterly) | 65.30M |
| EPS Diluted (Quarterly) | -1.01 |
| Gross Profit Margin (Quarterly) | 94.01% |
| Profit Margin (Quarterly) | -129.4% |
| Earnings Yield | -15.40% |
| Normalized Earnings Yield | -15.37 |